Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells
- PMID: 8558209
- DOI: 10.1200/JCO.1996.14.1.277
Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells
Abstract
Purpose: To study the toxicity and efficacy of combined granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) administration for mobilization of hematopoietic progenitor cells (HPCs).
Materials and methods: Cohorts of a minimum of five patients each were treated subcutaneously as follows: G-CSF 5 micrograms/kg on days 1 to 12 and GM-CSF at .5, 1, or 5 micrograms/kg on days 7 to 12 (cohorts 1, 2, and 3); GM-CSF 5 micrograms/kg on days 1 to 12 and G-CSF 5 micrograms/kg on days 7 to 12 (cohort 4); and G-CSF and GM-CSF 5 micrograms/kg each on days 1 to 12 (cohort 5). Ten-liter aphereses were performed on days 1 (baseline, pre-CSF), 5, 7, 11, and 13. Colony assays for granulocyte-macrophage colony-forming units (CFU-GM) and erythroid burst-forming units (BFU-E) were performed on each harvest.
Results: The principal toxicities were myalgias, bone pain, fever, nausea, and mild thrombocytopenia, but none was dose-limiting. Four days of treatment with either G-CSF or GM-CSF resulted in dramatic and sustained increases in the numbers of CFU-GM per kilogram collected per harvest that represented 35.6 +/- 8.9- and 33.7 +/- 13.0-fold increases over baseline, respectively. This increment was attributable both to increased numbers of mononuclear cells collected per 10-L apheresis and to increased concentrations of progenitors within each collection. The administration of G-CSF to patients already receiving GM-CSF (cohort 4) caused the HPC content to surge to nearly 80-fold the baseline (P = .024); the reverse sequence, ie, the addition of GM-CSF to G-CSF, was less effective. The CFU-GM content of the baseline aphereses correlated with the maximal mobilization achieved (r = .74, P = .001).
Conclusion: Combined G-CSF and GM-CSF administration effectively and predictably mobilizes HPCs and facilitates apheresis.
Similar articles
-
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.Exp Hematol. 1995 Dec;23(14):1520-6. Exp Hematol. 1995. PMID: 8542941
-
Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.J Clin Oncol. 2000 May;18(9):1824-30. doi: 10.1200/JCO.2000.18.9.1824. J Clin Oncol. 2000. PMID: 10784622 Clinical Trial.
-
Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.Ann Hematol. 1993 Dec;67(6):267-76. doi: 10.1007/BF01696346. Ann Hematol. 1993. PMID: 7506580 Clinical Trial.
-
Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells.Curr Opin Hematol. 2002 May;9(3):190-8. doi: 10.1097/00062752-200205000-00003. Curr Opin Hematol. 2002. PMID: 11953663 Review.
-
Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on the bactericidal functions of neutrophils.Curr Opin Hematol. 1997 May;4(3):183-90. doi: 10.1097/00062752-199704030-00005. Curr Opin Hematol. 1997. PMID: 9209834 Review.
Cited by
-
The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.Paediatr Drugs. 2003;5(10):673-84. doi: 10.2165/00148581-200305100-00003. Paediatr Drugs. 2003. PMID: 14510625 Review.
-
Cell Therapy in Patients with Critical Limb Ischemia.Stem Cells Int. 2015;2015:931420. doi: 10.1155/2015/931420. Epub 2015 Aug 2. Stem Cells Int. 2015. PMID: 26300924 Free PMC article. Review.
-
Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.Bone Marrow Transplant. 2006 Aug;38(4):275-84. doi: 10.1038/sj.bmt.1705441. Bone Marrow Transplant. 2006. PMID: 16883311 Free PMC article. Clinical Trial.
-
Coronary vessel development and insight towards neovascular therapy.Int J Exp Pathol. 2009 Jun;90(3):262-83. doi: 10.1111/j.1365-2613.2009.00646.x. Int J Exp Pathol. 2009. PMID: 19563610 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical